Statistical challenges in the evaluation of treatments for small patient populations

Science Translational Medicine

Volumn 5, Issue 178, 2013, Pages

  Korn, Edward L ^a   McShane, Lisa M ^a   Freidlin, Boris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROL GROUP; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FACTORIAL DESIGN; HUMAN; INTERIM MONITORING; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; PROCESS MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; STUDY DESIGN;

COST-BENEFIT ANALYSIS; CROSS-OVER STUDIES; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84876157480     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004018     Document Type: Review

References (97)

1. Office of Rare Diseases Research (NIH), http://rarediseases.info.nih.gov/ RareDiseaseList.aspx?PageID=1.
2. EMEA, Health EU - Rare diseases; http://ec.europa.eu/health-eu/health- problems/rare-diseases/index-en.htm.
3. European Medicines Agency, Guideline on clinical trials in small populations; www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003615.pdf.
4. Institute of Medicine, Small Clinical Trials: Issues and Challenges, C. H. Evans, S. T. Ildstat, Eds. (National Academy Press, Washington, DC, 2001); http://www.nap.edu/catalog/10078.html.
5. Office of Rare Diseases Research (NIH) and Office of Orphan Products Development (FDA), The science of small clinical trials lecture series; http://videocast.nih.gov/podcasts.asp?c=88.
6. Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Patient Registry Annual Report 2010 (Cystic Fibrosis Foundation, Bethesda, MD, 2011).
7. F. J. Accurso, S. M. Rowe, J. P. Clancy, M. P. Boyle, J.M. Dunitz, P. R. Durie, S. D. Sagel, D. B. Hornick, M. W. Konstan, S. H. Donaldson, R. B. Moss, J. M. Pilewski, R. C. Rubenstein, A. Z. Uluer, M. L. Aitken, S. D. Freedman, L. M. Rose, N. Mayer-Hamblett, Q. Dong, J. Zha, A. J. Stone, E. R. Olson, C. L. Ordoñez, P. W. Campbell, M. A. Ashlock, B. W. Ramsey, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991-2003 (2010).
8. B. W. Ramsey, J. Davies, N. G. McElvaney, E. Tullis, S. C. Bell, P. Døevínek, M. Griese, E. F. McKone, C. E. Wainwright, M. W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S. M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordoñez, J. S. Elborn; VX08-770-102 Study Group, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
9. R. Aherns, S. Rodriguez, K. Yen, J. C. Davies, VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551d-CFTR mutation. Pediatr. Pulmonol. 46 (Suppl. 34), 283, Abstract 203 (2011).
10. U.S. Food and Drug Administration, FDA approves Kalydeco to treat rare form of cystic fibrosis; www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm289633.htm.
11. B. Freidlin, E. L. Korn, R. Gray, A. Martin, Multi-arm clinical trials of new agents: Some design considerations. Clin. Cancer Res. 14, 4368-4371 (2008).
12. S. Green, J. Benedetti, J. Crowley, Clinical Trials in Oncology (CRC Press, Boca Raton, FL, ed. 2, 2003), pp. 86-90.
13. P. Armitage, C. K. McPherson, B. C. Rowe, Repeated significance tests on accumulating data. J. R. Stat Soc. Ser. A 132, 235-244 (1969).
14. B. Freidlin, E. L. Korn, S. L. George, Data monitoring committees and interim monitoring guidelines. Control Clin. Trials 20, 395-407 (1999).
15. K. K. G. Lan, D. L. Demets, Discrete sequential boundaries for clinical trials. Biometrika 70, 659-663 (1983).
16. P. C. O'Brien, T. R. Fleming, A multiple testing procedure for clinical trials. Biometrics 35, 549-556 (1979).
17. P. Armitage, Sequential Medical Trials (Wiley, New York, ed. 2, 1975).
18. W. A. Silverman, J. W. Fertig, A. P. Berger, The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics 22, 876-886 (1958).
19. B. Freidlin, E. L. Korn, Monitoring for lack of benefit: A critical component of a randomized clinical trial. J. Clin. Oncol. 27, 629-633 (2009).
20. S. S. Ellenberg, M. A. Eisenberger, An efficient design for phase III studies of combination chemotherapies. Cancer Treat. Rep. 69, 1147-1154 (1985).
21. S. Wieand, G. Schroeder, J. R. O'Fallon, Stopping when the experimental regimen does not appear to help. Stat. Med. 13, 1453-1458 (1994).
22. B. Freidlin, E. L. Korn, R. Gray, A general inefficacy interim monitoring rule for randomized clinical trials. Clin. Trials 7, 197-208 (2010).
23. S. S. Ellenberg, T. R. Fleming, D. L. DeMets, Data Monitoring Committees in Clinical Trials: A Practical Perspective (Wiley, Hoboken, NJ, 2002).
24. M. A. Smith, R. S. Ungerleider, E. L. Korn, L. Rubinstein, R. Simon, Role of independent datamonitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J. Clin. Oncol. 15, 2736-2743 (1997).
25. M. R. Harrison, R. L. Keller, S. B. Hawgood, J. A. Kitterman, P. L. Sandberg, D. L. Farmer, H. Lee, R. A. Filly, J. A. Farrell, C. T. Albanese, A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. N. Engl. J. Med. 349, 1916-1924 (2003).
26. D. A. Berry, S. G. Eick, Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Stat. Med. 14, 231-246 (1995).
27. J. Cornfield, M. Halperin, S. W. Greenhouse, An adaptive procedure for sequential clinical trials. J. Am. Stat. Assoc. 64, 759-770 (1969).
28. E. L. Korn, B. Freidlin, Outcome-adaptive randomization: Is it useful? J. Clin. Oncol. 29, 771-776 (2011).
29. E. L. Korn, B. Freidlin, On the usefulness of outcome-adaptive randomization reply. J. Clin. Oncol. 29, E393 (2011).
30. B. Freidlin, E. L. Korn, Adaptive randomization versus interim monitoring. J. Clin. Oncol. 31, 969-970 (2013).
31. G. R. Graff, K. Maguiness, J. McNamara, R. Morton, D. Boyd, K. Beckmann, D. Bennett, Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: A multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin. Ther. 32, 89-103 (2010).
32. J. A. Gelfand, R. J. Sherins, D. W. Alling, M. M. Frank, Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 295, 1444-1448 (1976).
33. G. Guyatt, D. Sackett, D. W. Taylor, J. Chong, R. Roberts, S. Pugsley, Determining optimal therapy - Randomized trials in individual patients. N. Engl. J. Med. 314, 889-892 (1986).
34. M. M. Frank, J. S. Sergent, M. A. Kane, D. W. Alling, Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 286, 808-812 (1972).
35. J. A. Lewis, Controlled trials in single subjects. 2. Limitations of use. BMJ 303, 175-176 (1991).
36. P. G. Good, Permutation Tests (Springer, New York, ed. 2, 2000).
37. B. I. Graubard, E. L. Korn, Choice of column scores for testing independence in ordered 2 × K contingency tables. Biometrics 43, 471-476 (1987).
38. J. D. Kalbfleish, R. L. Prentice, The Statistical Analysis of Failure Time Data (Wiley, New York, ed. 2, 2002).
39. R. Wang, S. W. Lagakos, R. J. Gray, Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics 11, 676-692 (2010).
40. G. W. Snedecor, W. G. Cochran, Statistical Methods (Iowa State University Press, Ames, IA, ed. 8, 1989), p. 127.
41. P. Armitage, G. Berry, Statistical Methods in Medical Research (Blackwell Scientific Publications, Oxford, ed. 3, 1994), pp. 137-141.
42. R. D. Boschloo, Raised conditional level of significance for the 2 × 2-table when testing the equality of two probabilities. Stat. Neerlandica 24, 1-9 (1970).
43. R. J. Temple, A regulatory authority's opinion about surrogate endpoints, in Clinical Measurement in Drug Evaluation, W. S. Nimmo, G. T. Tucker, Eds. (John Wiley & Sons, Chichester, 1995), pp. 1-22.
44. A. M. Hill, R. DeMasi, D. Dawson, Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir. Ther. 3, 139-145 (1998).
45. M. D. Hughes, M. J. Daniels, M. A. Fischl, S. Kim, R. T. Schooley, CD4 cell count as a surrogate endpoint in HIV clinical trials: A meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 12, 1823-1832 (1998).
46. Department of Health and Human Services (DHHS), Antiretroviral drugs using plasma HIV RNA measurements - Clinical considerations for accelerated and traditional approval, FDA Guidance For Industry; http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory-Information/Guidances/ucm070968.pdf.
47. T. R. Fleming, D. L. DeMets, Surrogate end points in clinical trials: Are we being misled? Ann. Intern. Med. 125, 605-613 (1996).
48. J. T. Bigger Jr., J. L. Fleiss, R. Kleiger, J. P. Miller, L. M. Rolnitzky, The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69, 250-258 (1984).
49. J. Mukharji, R. E. Rude, W. K. Poole, N. Gustafson, L. J. Thomas Jr., H. W. Strauss, A. S. Jaffe, J. E. Muller, R. Roberts, D. S. Raabe Jr., C. H. Croft, E. Passamani, E. Braunwald, J. T. Willerson, Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. Am. J. Cardiol. 54, 31-36 (1984).
50. J. N. Ruskin, The Cardiac Arrhythmia Suppression Trial (CAST). N. Engl. J. Med. 321, 386-388 (1989).
51. D. S. Echt, P. R. Liebson, L. B. Mitchell, R. W. Peters, D. Obias-Manno, A. H. Barker, D. Arensberg, A. Baker, L. Friedman, H. L. Greene, M. L. Huther, D. W. Richardson; CAST Investigators, Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
52. H. L. Greene, D. M. Roden, R. J. Katz, R. L. Woosley, D. M. Salerno, R. W. Henthorn, The Cardiac Arrhythmia Suppression Trial: First CAST ... then CAST-II. J. Am. Coll. Cardiol. 19, 894-898 (1992).
53. T. J. Moore, Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster (Simon and Schuster, New York, 1995), pp. 281-289.
54. L. V. Rubinstein, E. L. Korn, B. Freidlin, S. Hunsberger, S. P. Ivy, M. A. Smith, Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol. 23, 7199-7206 (2005).
55. E. L. Korn, B. Freidlin, J. S. Abrams, S. Halabi, Design issues in randomized phase II/III trials. J. Clin. Oncol. 30, 667-671 (2012).
56. E. L. Korn, P. S. Albert, L. M. McShane, Assessing surrogates as trial endpoints using mixed models. Stat. Med. 24, 163-182 (2005).
57. D. J. Sargent, H. S. Wieand, D. G. Haller, R. Gray, J. K. Benedetti,M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, G. Francini, A. Grothey, M. O'Connell, P. J. Catalano, C. D. Blanke, D. Kerr, E. Green, N. Wolmark, T. Andre, R. M. Goldberg, A. De Gramont, Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664-8670 (2005).
58. E. L. Korn, B. Freidlin, J. S. Abrams, Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J. Clin. Oncol. 29, 2439-2442 (2011).
59. E. L. Korn, B. Freidlin, J. S. Abrams, Survival is not a good outcome for randomized trials with effective subsequent therapies reply. J. Clin. Oncol. 29, 4720-4721 (2011).
60. B. J. Druker, M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, C. L. Sawyers, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
61. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, M. Talpaz, B. Druker, J. Goldman, S. G. O'Brien, N. Russell, T. Fischer, O. Ottmann, P. Cony-Makhoul, T. Facon, R. Stone, C. Miller, M. Tallman, R. Brown, M. Schuster, T. Loughran, A. Gratwohl, F. Mandelli, G. Saglio, M. Lazzarino, D. Russo, M. Baccarani, E. Morra; International STI571 CML Study Group, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
62. B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
63. J. R. Johnson, P. Bross, M. Cohen, M. Rothmann, G. Chen, A. Zajicek, J. Gobburu, A. Rahman, A. Staten, R. Pazdur, Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res. 9, 1972-1979 (2003).
64. S. G. O'Brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. E. Bolton, R. Capdeville, B. J. Druker; IRIS Investigators, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
65. I. Aksentijevich, M. Nowak, M. Mallah, J. J. Chae, W. T. Watford, S. R. Hofmann, L. Stein, R. Russo, D. Goldsmith, P. Dent, H. F. Rosenberg, F. Austin, E. F. Remmers, J. E. Balow Jr., S. Rosenzweig, H. Komarow, N. G. Shoham, G. Wood, J. Jones, N. Mangra, H. Carrero, B. S. Adams, T. L. Moore, K. Schikler, H. Hoffman, D. J. Lovell, R. Lipnick, K. Barron, J. J. O'Shea,D. L. Kastner, R. Goldbach-Mansky, De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46, 3340-3348 (2002).
66. J. Feldmann, A. M. Prieur, P. Quartier, P. Berquin, S. Certain, E. Cortis, D. Teillac-Hamel, A. Fischer, G. de Saint Basile, Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71, 198-203 (2002).
67. R. Goldbach-Mansky, N. J. Dailey, S. W. Canna, A. Gelabert, J. Jones, B. I. Rubin, H. J. Kim, C. Brewer, C. Zalewski, E. Wiggs, S. Hill, M. L. Turner, B. I. Karp, I. Aksentijevich, F. Pucino, S. R. Penzak, M. H. Haverkamp, L. Stein, B. S. Adams, T. L. Moore, R. C. Fuhlbrigge, B. Shaham, J. N. Jarvis, K. O'Neil, R. K. Vehe, L. O. Beitz, G. Gardner, W. P. Hannan, R. W. Warren, W. Horn, J. L. Cole, S. M. Paul, P. N. Hawkins, T. H. Pham, C. Snyder, R. A. Wesley, S. C. Hoffmann, S. M. Holland, J. A. Butman, D. L. Kastner, Neonatal-onset multisystem inflammatory disease responsive to interleukin-1b inhibition. N. Engl. J. Med. 355, 581-592 (2006).
68. C. H. Sibley, N. Plass, J. Snow, E. A. Wiggs, C. C. Brewer, K. A. King, C. Zalewski, H. J. Kim, R. Bishop, S. Hill, S. M. Paul, P. Kicker, Z. Phillips, J. G. Dolan, B. Widemann, N. Jayaprakash, F. Pucino, D. L. Stone, D. Chapelle, C. Snyder, J. A. Butman, R. Wesley, R. Goldbach-Mansky, Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine threeand five-year outcomes. Arthritis Rheum. 64, 2375-2386 (2012).
69. S. Schreiber, S. Nikolaus, J. Hampe, J. Hamling, I. Koop, B. Groessner, H. Lochs, A. Raedler, Tumour necrosis factor a and interleukin 1b in relapse of Crohn's disease. Lancet 353, 459-461 (1999).
70. J. Hyams, W. Crandall, S. Kugathasan, A. Griffiths, A. Olson, J. Johanns, G. Liu, S. Travers, R. Heuschkel, J. Markowitz, S. Cohen, H. Winter, G. Veereman-Wauters, G. Ferry, R. Baldassano, Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132, 863-873 (2007).
71. The necessity and challenges of clinical research involving children, in The Ethical Conduct of Clinical Research Involving Children, M. J. Field, R. E. Berman, Eds. (National Academies Press, Washington, DC, 2004), pp. 58-92.
72. P. C. Adamson, S. M. Blaney, New approaches to drug development in pediatric oncology. Cancer J. 11, 324-330 (2005).
73. J. Zujewski, A. Nelson, J. Abrams, Much ado about not ... enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer. J. Natl. Cancer Inst. 90, 200-209 (1998).
74. M. M. Mello, T. A. Brennan, The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff. 20, 101-117 (2001).
75. G. N. Hortobagyi, What is the role of high-dose chemotherapy in the era of targeted therapies? J. Clin. Oncol. 22, 2263-2266 (2004).
76. K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C.Wang, S. M. Davies, P. S. Gaynon, M. Trigg, R. Rutledge, L. Burden, D. Jorstad, A. Carroll, N. A. Heerema, N. Winick, M. J. Borowitz, S. P. Hunger, W. L. Carroll, B. Camitta, Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group Study. J. Clin. Oncol. 27, 5175-5181 (2009).
77. A. R. Feinstein, D. M. Sosin, C. K. Wells, The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312, 1604-1608 (1985).
78. C. D. Fraser Jr., R. D. B. Jaquiss, D. N. Rosenthal, T. Humpl, C. E. Canter, E. H. Blackstone, D. C. Naftel, R. N. Ichord, L. Bomgaars, J. S. Tweddell, M. P. Massicotte, M. W. Turrentine, G. A. Cohen, E. J. Devaney, F. B. Pearce, K. E. Carberry, R. Kroslowitz, C. S. Almond; Berlin Heart Study Investigators, Prospective trial of a pediatric ventricular assist device. N. Engl. J. Med. 367, 532-541 (2012).
79. C. S. Almond, H. Buchholz, P. Massicotte, R. Ichord, D. N. Rosenthal, K. Uzark, R. D. B. Jaquiss, R. Kroslowitz, M. B. Kepler, A. Lobbestael, D. Bellinger, E. D. Blume, C. D. Fraser Jr., R. H. Bartlett, R. Thiagarajan, K. Jenkins, Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: Study design and rationale. Am. Heart J. 162, 425-435 (2011).
80. U.S. Food and Drug Administration, FDA Executive Summary: EXCOR Pediatric Ventricular Assist Device; http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ CirculatorySystemDevicesPanel/UCM263168.pdf.
81. U.S. Food and Drug Administration, Transcript of July 21, 2011 FDA Circulatory System Devices Meeting; http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM269475.pdf.
82. CFR: Code of Federal Regulations, 814.3(n); http://www.gpo.gov/fdsys/pkg/ CFR-2003-title21-vol8/pdf/CFR-2003-title21-vol8-part814.pdf.
83. U.S. Food and Drug Administration, Humanitarian Device Exemption; http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ HowtoMarketYourDevice/PremarketSubmissions/HumanitarianDeviceExemption/default. htm.
84. B. Wilcken, Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? J. Inherit. Metab. Dis. 24, 291-298 (2001).
85. E. L. Korn, B. Freidlin, Conditional power calculations for clinical trials with historical controls. Stat. Med. 25, 2922-2931 (2006).
86. D. D. Von Hoff, There are no bad anticancer agents, only bad clinical trial designs - Twentyfirst Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079-1086 (1998).
87. J. Verweij, P. G. Casali, J. Zalcberg, A. LeCesne, P. Reichardt, J. Y. Blay, R. Issels, A. van Oosterom, P. C. W. Hogendoorn, M. Van Glabbeke, R. Bertulli, I. Judson, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364, 1127-1134 (2004).
88. J. R. Zalcberg, J. Verweij, P. G. Casali, A. Le Cesne, P. Reichardt, J. Y. Blay, M. Schlemmer, M. Van Glabbeke, M. Brown, I. R. Judson; EORTC Soft Tissue Bone Sarcoma Group; Italian Sarcoma Group; Australasian Gastrointestinal Trial Group, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer 41, 1751-1757 (2005).
89. L. B. Gordon, M. E. Kleinman, D. T. Miller, D. S. Neuberg, A. Giobbie-Hurder, M. Gerhard-Herman, L. B. Smoot, C. M. Gordon, R. Cleveland, B. D. Snyder, B. Fligor, W. R. Bishop, P. Statkevich, A. Regen, A. Sonis, S. Riley, C. Ploski, A. Correia, N. Quinn, N. J. Ullrich, A. Nazarian, M. G. Liang, S. Y. Huh, A. Schwartzman, M. W. Kieran, Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. U.S.A. 109, 16666-16671 (2012).
90. L. B. Gordon, K. M. McCarten, A. Giobbie-Hurder, J. T. Machan, S. E. Campbell, S. D. Berns, M. W. Kieran, Disease progression in Hutchinson-Gilford progeria syndrome: Impact on growth and development. Pediatrics 120, 824-833 (2007).
91. M. A. Hamburg, F. S. Collins, The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
92. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R.G. Maki, S. H. I. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
93. European Society for Medical Oncology (ESMO), Crizotinib, European Society for Medical Oncology 2012 press release; http://www.esmo.org/about-esmo/ press-office/esmo-2012-press-releases/view.html?tx-ttnews%5Btt-news%5D= 1621&tx-ttnews%5BbackPid%5D=2272&cHash=3b7779d041.
94. NCT01306045, Molecular profiling and targeted therapy for advanced non-small cell lung cancer, small cell lung cancer, and thymic malignancies; http://www.clinicaltrials.gov/ct2/results?term=NCT01306045&Search=Search.
95. L. M. McShane, S. Hunsberger, A. A. Adjei, Effective incorporation of biomarkers into phase II trials. Clin. Cancer Res. 15, 1898-1905 (2009).
96. Y. J. Bang, E. Van Cutsem, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y. K. Kang; ToGA Trial Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
97. S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz, PLX4032 in metastatic colorectal cancer patients with BRAF tumors, J. Clin. Oncol. 28 (Suppl. 15), Abstract 3534 (2010).